OR4C46 Inhibitors
OR4C46 inhibitors are a distinctive group of compounds that interact with specific signaling pathways or cellular processes to inhibit the functional activity of the OR4C46 protein. Quinpirole acts on D2-like dopamine receptors, which are negatively coupled to adenylyl cyclase, thereby reducing cAMP levels that could be critical for OR4C46 activity. SCH-23390 operates through a related mechanism, antagonizing D1 dopamine receptors to lower adenylyl cyclase activity and thus cAMP concentration, potentially reducing OR4C46 function if it operates through the cAMP pathway.
Compounds like KT5720 target components downstream of cAMP, such as PKA, which when inhibited could decrease OR4C46 activity if its signaling is PKA-dependent. ZD7288 affects membrane potential by blocking HCN channels, which could modulate OR4COR4C46 inhibitors encompass a range of chemical entities that indirectly attenuate the activity of OR4C46 by influencing various biochemical and cellular pathways. Quinpirole, by activating D2-like receptors, leads to reduced adenylyl cyclase activity and subsequent lower cAMP levels, potentially diminishing OR4C46 signaling if it is linked to the cAMP pathway. SCH-23390, a dopamine D1 receptor antagonist, similarly cuts down adenylyl cyclase action, leading to decreased cAMP and possibly attenuated OR4C46 activity. KT5720, as a PKA inhibitor, can suppress further downstream effects of cAMP signaling, which would indirectly lessen OR4C46 activity if PKA is involved in its signaling cascade. ZD7288, by inhibiting HCN channels, could alter neuronal excitability and indirectly modulate OR4C46 activity if it is sensitive to changes in membrane potential.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Quinpirole hydrochloride | 85798-08-9 | sc-253339 | 10 mg | $141.00 | 1 | |
Quinpirole is a dopamine agonist that preferentially activates D2-like receptors, which are known to inhibit adenylyl cyclase activity. Since OR4C46 is a G protein-coupled receptor (GPCR) that can be coupled to inhibitory G-proteins, activation of D2-like receptors by quinpirole can lead to a decrease in cyclic AMP (cAMP) levels, which could reduce OR4C46 signaling if it is coupled to the cAMP pathway. | ||||||
SCH 23390 | 125941-87-9 | sc-200408 sc-200408A | 5 mg 25 mg | $179.00 $733.00 | 2 | |
SCH-23390 is a dopamine D1 receptor antagonist that blocks the D1 receptor-mediated activation of adenylyl cyclase. Inhibition of adenylyl cyclase decreases cAMP levels, which could lead to reduced activity of OR4C46 if it signals through the cAMP pathway. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $138.00 $220.00 $972.00 | 47 | |
KT5720 is a potent inhibitor of protein kinase A (PKA), which is activated by cAMP. If OR4C46's functional activity is cAMP-dependent, inhibition of PKA by KT5720 would lead to reduced OR4C46 signaling. | ||||||
ZD 7288 | 133059-99-1 | sc-361419 sc-361419A | 10 mg 50 mg | $211.00 $552.00 | ||
ZD7288 is an HCN channel blocker that inhibits hyperpolarization-activated cyclic nucleotide-gated channels. By decreasing the influence of these channels on membrane potential, ZD7288 could indirectly inhibit OR4C46 if it is modulated by changes in neuronal excitability. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
L-NAME is a nitric oxide synthase inhibitor that reduces the production of nitric oxide (NO). If OR4C46's activity is modulated by NO signaling pathways, L-NAME would reduce its activity by limiting NO availability. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is an inhibitor of protein kinase C (PKC). If OR4C46 is regulated by PKC-mediated phosphorylation, the inhibition of PKC by chelerythrine would result in decreased OR4C46 activity. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin is a P2 receptor antagonist that can inhibit the action of extracellular ATP on purinergic receptors. If OR4C46 interacts with purinergic signaling pathways, suramin could inhibit OR4C46 activity by blocking these receptors. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK). If OR4C46 is involved in pathways that regulate cytoskeletal changes via MLCK, inhibition by ML-7 could lead to reduced OR4C46 activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go 6983 is a broad-spectrum PKC inhibitor. Similar to chelerythrine, if OR4C46 is modulated by PKC, Go 6983 would inhibit its activity through PKC inhibition. | ||||||
YM 254890 | 568580-02-9 | sc-507356 | 1 mg | $510.00 | ||
YM-254890 is a selective inhibitor of the Gαq/11 protein. If OR4C46 signals via the Gαq/11 pathway, inhibition of this G protein by YM-254890 would result in decreased OR4C46 signaling. | ||||||